In several clinical trials, the anti-CD22 CAR-T cell therapy has shown excellent efficacy in R/R B-ALL and R/R DLBCL patients who have failed in previous anti-CD19 CAR-T cell therapy (24–26). The gene discussed is CD22; the disease is acute lymphoblastic leukemia.